Two cases of Ticlopidine-induced neutropenia in patients with cardiovascular disease
Korean Circulation Journal
;
: 280-283, 1998.
Artigo
em Coreano
| WPRIM
| ID: wpr-136833
ABSTRACT
Ticlopidine is an antiplatelet agent used as a drug to prevent the recurrence of cerebral infarction or ischemic heart disease. Close attention has recently been paid to the superiority of this drug to aspirin in the prevention of stroke. Its mechanism of action differs from aspirin, dipyridamole, and sulfinpyrazone. Inhibition of the adenosine diphosphate induced pathway of platelet aggregation, along with the activation of adenylate cyclase and suppression of platelet-activating factor and thromboxane A2, are the postulated mechanisms of action of ticlopidine. Because ticlopidine causes neutropenia and agranulocytosis in roughly 1% of treated patients, usually within the first 3 months of treatment, this drug has been reserved for patients intolerant to aspirin therapy. We reported two cases of ticlopidine-induced neutropenia and one patient hospitalized with severe neutropenia and pneumonia.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Pneumonia
/
Recidiva
/
Tromboxano A2
/
Ticlopidina
/
Doenças Cardiovasculares
/
Difosfato de Adenosina
/
Infarto Cerebral
/
Adenilil Ciclases
/
Agregação Plaquetária
/
Sulfimpirazona
Limite:
Humanos
Idioma:
Coreano
Revista:
Korean Circulation Journal
Ano de publicação:
1998
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS